Lactosorb, a bioresorbable fixation system, is revolutionizing craniofacial surgery, particularly in frontal cranioosteoplasty. It supports bone fixation and resorbs into the body over 12 to 18 months, utilizing poly(lactic-co-glycolic acid) (PLGA) for its unique properties.
Role of PLGA in Lactosorb
PLGA, a copolymer of lactic and glycolic acid, is biodegradable and biocompatible, making it ideal for temporary implants. The 82:18 PLGA composition (82% lactic acid, 18% glycolic acid) balances hydrophilicity, mechanical strength, and degradation rate.
Key Characteristics of PLGA 82:18
- Molecular Weight: 70,000 to 100,000 Da, ensuring strength and predictable degradation.
- Intrinsic Viscosity (IV): 0.8 to 1.2 dL/g, influencing processing and performance.
- End-Group Termination: Acid-terminated for faster hydrolytic degradation, aligning with the bone-healing timeline.
Application in Frontal Cranioosteoplasty
Lactosorb provides temporary support, gradually transfers mechanical load to healing bone, and minimizes inflammatory responses. Its biocompatibility and controlled resorption make it ideal for reconstructing or reshaping the frontal bone.
Conclusion
Lactosorb’s use of PLGA 82:18 offers a blend of strength, biocompatibility, and predictable resorption. This innovation underscores the vital role of advanced polymers in medical technology, improving patient outcomes in craniofacial surgery.